Zobrazeno 1 - 10
of 15
pro vyhledávání: '"ROMAN FREIXA-PAMIAS"'
Autor:
Francisco Marin, Marcelo Sanmartin Fernandez, Gonzalo Baron-Esquivias, Vivencio Barrios, Inaki Lekuona, Alejandro I Perez-Cabeza, Jaime Masjuan, Esther Recalde del Vigo, Jose Manuel Vazquez Rodriguez, Roman Freixa-Pamias, Vanessa Roldan Schilling, Fernando Arribas, Carles Rafols Priu, Manuel Anguita Sanchez
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 3 (2023)
Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospec
Externí odkaz:
https://doaj.org/article/eda29beddbb14fddb75450f8299c618d
Publikováno v:
Revista Española de Cardiología (English Edition). 76:287-293
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e165b98eb0a608b6c19049cc2ec4454
https://doi.org/10.1016/j.rec.2022.10.010
https://doi.org/10.1016/j.rec.2022.10.010
Autor:
Marcelo Sanmartín Fernández, Manuel Anguita Sánchez, Fernando Arribas, Gonzalo Barón-Esquivias, Vivencio Barrios, Juan Cosin-Sales, María Asunción Esteve-Pastor, Roman Freixa-Pamias, Iñaki Lekuona, Alejandro I. Pérez-Cabeza, Isabel Ureña, José Manuel Vázquez Rodríguez, Carles Rafols Priu, Francisco Marin
Publikováno v:
Cardiology Journal. 29:601-609
The aim of the study was to evaluate the performance of the 2MACE in patients with atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE.This was a post-authorization and observational study of AF adults treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bab2e783b7194357d4a445e71d56f35
https://doi.org/10.5603/cj.a2022.0044
https://doi.org/10.5603/cj.a2022.0044
Autor:
Alberto Cordero, Mª. Rosa Fernández Olmo, Gustavo A. Cortez Quiroga, Cesar Romero‐Menor, Lorenzo Fácila, José Seijas‐Amigo, Juan Rondán Murillo, Miriam Sandin, Moisés Rodríguez‐Mañero, María C. Bello Mora, Alfonso Valle, Aisa Fornovi, Roman Freixa Pamias, Jordi Bañeras, Pedro Blanch García, María Milagros Clemente Lorenzo, Sergio Sánchez‐Álvarez, Luis López‐Rodríguez, José R. González‐Juanatey
Publikováno v:
European Journal of Clinical Investigation. 52
Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, the effect of other lipid parameters, such as chole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c12d677d01d1077dfc9fa8b223f85fb9
https://doi.org/10.1111/eci.13863
https://doi.org/10.1111/eci.13863
Autor:
Pedro Armario, Roman Freixa-Pamias
Publikováno v:
Clínica e Investigación en Arteriosclerosis. 33:254-256
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a67d75359f41ad48b197552f7c1380fa
https://doi.org/10.1016/j.arteri.2021.07.001
https://doi.org/10.1016/j.arteri.2021.07.001
Autor:
José Seijas-Amigo, Alberto Cordero, Rosa F. Olmo, Gustavo A. Cortez Quiroga, Lorenzo Fácila, Ángel Salgado-Barreira, Francisco Reyes-Santías, Cesar Romero-Menor, Juan Rondán Murillo, Moisés Rodríguez-Mañero, María C. Bello Mora, Alfonso Valle, Miriam Sandin, Roman Freixa Pamias, Jordi Bañeras, Pedro Blanch García, Milagros Clemente Lorenzo, Sergio Sánchez-Alvarez, Luis López-Rodríguez, José R. González-Juanatey
Publikováno v:
Journal of cardiovascular pharmacology. 81(1)
Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid is a novel oral drug in the therapeutic armamentarium which is able to reduce LDLc. The objectives of this study were (1) to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5758aa8fcd5dc291262ba7930a60066f
https://pubmed.ncbi.nlm.nih.gov/36219195
https://pubmed.ncbi.nlm.nih.gov/36219195
Autor:
Carlos Escobar, Josep Gómez Lara, Javier Escaned, Antoni Carol Ruiz, Enrique Gutiérrez Ibañes, Leticia Fernández Friera, Sergio Raposeiras-Roubín, Joaquín Alonso Martín, Jaume Agüero, Jose María Gámez, Pablo Jorge-Pérez, Román Freixa-Pamias, Vivencio Barrios, Ignacio Cruz González, Amparo Martínez Monzonís, Ana Viana Tejedor
Publikováno v:
REC: Interventional Cardiology (English Ed.), Vol 6, Iss 2, Pp 106-116 (2024)
ABSTRACT A substantial number of patients undergoing coronary angiography for angina or ischemia in noninvasive tests have coronary arteries without lesions or with nonsignificant stenosis. Many of these patients have nonobstructive myocardial ischem
Externí odkaz:
https://doaj.org/article/53febb838b024cb185de4790e9790d7f
Autor:
Carlos Escobar, Josep Gómez Lara, Javier Escaned, Antoni Carol Ruiz, Enrique Gutiérrez Ibañes, Leticia Fernández Friera, Sergio Raposeiras-Roubín, Joaquín Alonso Martín, Jaume Agüero, Jose María Gámez, Pablo Jorge-Pérez, Román Freixa-Pamias, Vivencio Barrios, Ignacio Cruz González, Amparo Martínez Monzonís, Ana Viana Tejedor
Publikováno v:
REC: Interventional Cardiology, Vol 6, Iss 2, Pp 106-116 (2024)
RESUMEN Un número importante de aquellos pacientes en quienes se realiza coronariografía por angina o isquemia presentan en pruebas no invasivas arterias coronarias sin lesiones o con estenosis no significativas. Muchos de estos pacientes tienen is
Externí odkaz:
https://doaj.org/article/47efaa1b986342bea3e8208295cd14cf
Autor:
Ahmet Celik, Maria Christiane Valeria Braga Braile-Sternieri, Denis Andreev, Yury Grinshtein, Andrzej Lubiński, Hans Prozesky, Olga Mirolyubova, Yaroslav Malynovsky, Michel GALINIER, Andrzej Madej, Felix Perez-Villa, Dariusz Kosior, Mandeep Mehra, Elena Shutemova, John Cleland, PASCUAL BORDES SISCAR, Henk Verheul, ROMAN FREIXA-PAMIAS
Publikováno v:
New England Journal of Medicine, 379(14), 1332-1342. MASSACHUSETTS MEDICAL SOC
Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa09983d0a8f132bd68948e856db311e
http://hdl.handle.net/11379/518287
http://hdl.handle.net/11379/518287
Autor:
Aleksandr Svistov, Oksana Drapkina, William Strain, YAN CARLOS DUARTE VERA, Lars Kober, Manuel Gómez-Bueno, Konstantin Ramshev, Miguel Urina, Kamal Sharma, Zbigniew Pijanowski, Peter Olexa, Celina Wojciechowska, Albert HAGEGE, Jan Krupicka, Marcelo Sanmartin-Fernandez, Michel GALINIER, Vladimir Rafalskiy, John Mcmurray, Roman Libis, Angus Nightingale, Fernando Lanas, MICHELE SENNI, Richard Bogle, Marta Negrusz-Kawecka, Jose Silva-Cardoso, Michael Zile, José Albuquerque De Figueiredo Neto, Biykem Bozkurt, Philippe Gosse, Elena Shutemova, Fernando Manzur, Raj Mohindra, Gian Battista Danzi, DİLEK URAL, ROMAN FREIXA-PAMIAS
Publikováno v:
European Journal of Heart Failure, 15, 1062-73
European Journal of Heart Failure
European Journal of Heart Failure, 15, 9, pp. 1062-73
European Journal of Heart Failure
European Journal of Heart Failure, 15, 9, pp. 1062-73
Item does not contain fulltext AIMS: Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin-angiotensin-aldosterone system (RAAS), potentially beneficial counte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ddb1d56f1df2dcf2a4f9183f1bb9f45
https://doi.org/10.1093/eurjhf/hft052
https://doi.org/10.1093/eurjhf/hft052